Results of Resmetirom fibrosis targeting study using STAM™ model
Recently, we have obtained the results of a study of resmetirom for the treatment of fibrosis using STAMTM-HCC/IO+ model, and would like to share them with you.
Resmetirom treatment confirmed improvement of steatosis score, NAFLD Activity score and fibrosis resolution effects.
Thus, the STAMTM-HCC/IO+ model has been shown to show similar improvements in the analysis items evaluated in clinical trials with the approved resmetirom.
With this data, it is now possible to use resmetirom as a positive control in the fibrosis targeting study using STAMTM-HCC/IO+. By including resmetirom in the study design, you can directly compare your test substance with resmetirom.